Los Angeles Capital Management & Equity Research Inc. grew its stake in shares of Alkermes PLC (NASDAQ:ALKS) by 206.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 261,977 shares of the company’s stock after acquiring an additional 176,442 shares during the quarter. Los Angeles Capital Management & Equity Research Inc. owned about 0.17% of Alkermes PLC worth $13,319,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Atlantic Trust Group LLC increased its holdings in shares of Alkermes PLC by 4.9% during the second quarter. Atlantic Trust Group LLC now owns 167,717 shares of the company’s stock valued at $9,722,000 after acquiring an additional 7,807 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Alkermes PLC by 1.7% in the second quarter. Bank of New York Mellon Corp now owns 1,377,593 shares of the company’s stock valued at $79,859,000 after buying an additional 23,506 shares during the last quarter. Legal & General Group Plc boosted its position in Alkermes PLC by 10.2% in the second quarter. Legal & General Group Plc now owns 654,744 shares of the company’s stock valued at $37,956,000 after buying an additional 60,624 shares during the last quarter. Tredje AP fonden boosted its position in Alkermes PLC by 85.5% in the second quarter. Tredje AP fonden now owns 30,510 shares of the company’s stock valued at $1,769,000 after buying an additional 14,060 shares during the last quarter. Finally, Aviva PLC boosted its position in Alkermes PLC by 5.4% in the second quarter. Aviva PLC now owns 88,159 shares of the company’s stock valued at $5,111,000 after buying an additional 4,525 shares during the last quarter. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Shares of Alkermes PLC (NASDAQ:ALKS) opened at $47.75 on Friday. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23. Alkermes PLC has a 52-week low of $46.42 and a 52-week high of $63.40.

Alkermes PLC (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative return on equity of 7.27% and a negative net margin of 20.12%. The business had revenue of $217.40 million for the quarter, compared to analyst estimates of $231.29 million. During the same quarter in the prior year, the firm posted ($0.09) EPS. The business’s quarterly revenue was up 20.6% compared to the same quarter last year. analysts predict that Alkermes PLC will post -0.59 EPS for the current year.

A number of equities research analysts recently commented on ALKS shares. ValuEngine lowered Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. BidaskClub lowered Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Zacks Investment Research upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC set a $69.00 target price on Alkermes PLC and gave the company a “buy” rating in a research report on Friday, August 25th. Finally, Barclays PLC lowered Alkermes PLC from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $66.00 to $50.00 in a research report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $63.55.

In other news, SVP James M. Frates sold 20,932 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $47.58, for a total transaction of $995,944.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard F. Pops sold 50,000 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $48.87, for a total value of $2,443,500.00. The disclosure for this sale can be found here. Insiders have sold a total of 102,498 shares of company stock worth $5,018,010 in the last quarter. Insiders own 5.34% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Alkermes PLC (ALKS) Stake Boosted by Los Angeles Capital Management & Equity Research Inc.” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2017/11/17/alkermes-plc-alks-stake-boosted-by-los-angeles-capital-management-equity-research-inc.html.

Alkermes PLC Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.